Daily Newsletter

22 August 2023

Share with colleague
Subscribe

Daily Newsletter

22 August 2023

Share with colleague
Subscribe

Spotlight

Telemedicine is yet to overcome diversity challenges in dermatology clinical trials

Even though telemedicine is the most used DCT component, it lacks a personal touch and ability to represent all skin tones in dermatology clinical trials.

Latest news

FDA clears Incannex’s IND for trial of obstructive sleep apnoea therapy

The pivotal trial will evaluate the effect of IHL-42X in patients who are naive to positive airway pressure treatment.

22 August 2023

FDA pauses Gilead’s magrolimab studies in acute myeloid leukaemia

The news follows the pharma company’s decision to terminate a Phase III trial of the drug in myelodysplastic syndromes due to poor efficacy.

22 August 2023

Signal: Porosome files comprehensive patent for therapies to treat cystic fibrosis and other health conditions

The biopharma company has filed a comprehensive patent to address cystic fibrosis and other ailments.

22 August 2023

CARsgen and Moderna collaborate to evaluate cancer combo therapy

Multiple clinical studies of CT041 are currently ongoing in China and North America.

22 August 2023

Ocugen plans two Phase I/II trials in macular disease

The gene therapy trials in geographic atrophy and Stargardt disease are planned to start by the end of 2023.

22 August 2023

Recce commences patient dosing in diabetic foot infections therapy trial

Participants will be monitored face-to-face in the High-Risk Foot Clinic at Liverpool Hospital on days seven and 14 of the trial.

22 August 2023

Phio’s partners dose first patient in cancer combo therapy trial

The study intends to assess the safety of AgonOx’s AGX148 alone and combined with Phio’s PD-1 silencing PH-762.

22 August 2023

Multiple Myeloma (MM) pipeline is dominated by CAR-T cells

The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.